152 related articles for article (PubMed ID: 19665156)
1. The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
Wolfesberger B; Tonar Z; Gerner W; Skalicky M; Heiduschka G; Egerbacher M; Thalhammer JG; Walter I
Res Vet Sci; 2010 Feb; 88(1):94-100. PubMed ID: 19665156
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
3. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Jane EP; Premkumar DR; Pollack IF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
[TBL] [Abstract][Full Text] [Related]
6. Effects of lycopene on proliferation and death of canine osteosarcoma cells.
Wakshlag JJ; Balkman CE
Am J Vet Res; 2010 Nov; 71(11):1362-70. PubMed ID: 21034328
[TBL] [Abstract][Full Text] [Related]
7. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2007 May; 73(9):1308-17. PubMed ID: 17266941
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
10. In vitro reversal of glutathione-S-transferase-mediated resistance in canine osteosarcoma (COS31) cells.
Shoieb AM; Hahn KA; Van Laack RL; Barnhill MA
In Vivo; 1998; 12(5):455-62. PubMed ID: 9827351
[TBL] [Abstract][Full Text] [Related]
11. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Dal Lago L; D'Hondt V; Awada A
Oncologist; 2008 Aug; 13(8):845-58. PubMed ID: 18695262
[TBL] [Abstract][Full Text] [Related]
12. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Tran MA; Smith CD; Kester M; Robertson GP
Clin Cancer Res; 2008 Jun; 14(11):3571-81. PubMed ID: 18519791
[TBL] [Abstract][Full Text] [Related]
13. Use of an artificial lymphatic system during carboplatin infusion to improve canine osteosarcoma blood flow and clinical response.
DiResta GR; Aiken SW; Brown HK; Bergman PJ; Hohenhaus A; Ehrhart EJ; Baer K; Healey JH
Ann Surg Oncol; 2007 Aug; 14(8):2411-21. PubMed ID: 17503157
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.
Plastaras JP; Kim SH; Liu YY; Dicker DT; Dorsey JF; McDonough J; Cerniglia G; Rajendran RR; Gupta A; Rustgi AK; Diehl JA; Smith CD; Flaherty KT; El-Deiry WS
Cancer Res; 2007 Oct; 67(19):9443-54. PubMed ID: 17909054
[TBL] [Abstract][Full Text] [Related]
15. Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model.
Scharf VF; Farese JP; Siemann DW; Abbott JR; Kiupel M; Salute ME; Milner RJ
Anticancer Drugs; 2014 Mar; 25(3):332-9. PubMed ID: 24304691
[TBL] [Abstract][Full Text] [Related]
16. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells.
Wolfesberger B; Walter I; Hoelzl C; Thalhammer JG; Egerbacher M
Res Vet Sci; 2006 Jun; 80(3):308-16. PubMed ID: 16182328
[TBL] [Abstract][Full Text] [Related]
18. Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.
Hosoya K; Murahari S; Laio A; London CA; Couto CG; Kisseberth WC
Am J Vet Res; 2008 Apr; 69(4):519-26. PubMed ID: 18380584
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
Yoshitani K; Honoki K; Morishita T; Kido A; Miyauchi Y; Mii Y; Takakura Y
In Vivo; 2003; 17(3):255-8. PubMed ID: 12929576
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]